Medical/Pharmaceuticals
Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma
SHANGHAI and HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-11-02 08:30
4462
SOPHiA GENETICS Launches SOPHiA DDM™ for SureSelect Human All Exon v8
New bioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven ...
2021-11-01 20:03
3096
MGI Unveils Performance Upgrades for its Sequencing Platforms* and Customized ATOPlex Platform at the 16th International Conference on Genomics
QINGDAO, China, Nov. 1, 2021 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a global life science leader and innovator, introduced a series of performance upgrades for its gene sequencing platforms* and a new multiplex PCR platform at the 16th International Conference on Genomics (ICG-16) held inQingd...
2021-11-01 19:52
2443
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
GAITHERSBURG, Md. and PUNE, India, Nov. 1, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine ma...
2021-11-01 18:57
5774
WuXi Biologics Launches a New GMP Commercial Drug Product Facility
* Enhances drug product services for projects at various stages, with an emphasis on late and commercial stage production * Increases up to 60 million vials for commercial drug production per year * Consolidates WuXi Biologics' pioneering the application of innovative technologies such as si...
2021-11-01 10:19
7223
Suzhou Ribo Life Science Co. Ltd. Adopts ArisGlobal's LifeSphere® MultiVigilance to Advance Data Management from Clinical Trials
Innovative R&D company selects LifeSphere by ArisGlobal to further develop its safety capabilities MIAMI, Nov. 1, 2021 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end drug development technology platform LifeSphe...
2021-11-01 09:00
4003
Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
SHANGHAI and HONG KONG, Nov. 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-11-01 08:40
4981
Gannex Announces U.S. IND Approval of ASC43F, a First-in-Class Dual-Target Fixed-Dose Combination for NASH
SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC43F, a first-...
2021-11-01 08:30
3569
Farrer Park Hospital Introduced Actinium-225 PSMA Nuclear Therapy for Advanced Prostate Cancer
Earlier trials using Actinium-225 PSMA showed an improved biochemical response and better cancer-killing effects as Actinium-225 PSMA uses a much more potent radioactive ligand. SINGAPORE, Nov. 1, 2021 /PRNewswire/ -- Prostate cancer is the 3rd most common cancer among Singaporean men. Every day...
2021-11-01 08:15
2633
Everest Medicines Announces Share Repurchase Transaction Details
SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that it ...
2021-11-01 08:00
3213
Award-winning abstracts confirm benefits of Elekta Unity in precision radiation therapy
CHICAGO, Oct. 29, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced the presentation of new award-winning abstracts supporting the many benefits of Elekta Unity in treating cancer patients using precision radiation therapy. The abstracts add to the growing body of data manifesting Elekta Un...
2021-10-29 22:15
3927
Baylor and Harvard Researchers Partner in Long-Term, Global Study of Human Flourishing
Researchers at Harvard University and Baylor University launch the largest initiative of its kind to investigate the determinants of human flourishing. "The Global Flourishing Study" is a $43.4 million, five-year annual study of 240,000 individuals in 22 countries across a broad range of well-bei...
2021-10-29 19:00
5406
3M Health Care and Thermo Fisher Scientific Collaborate to Increase Process Efficiency and Scalability in Commercial Therapeutic Manufacturing
- Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers - Solution enables manufacturers to optimize manufacturing capacity, quality, efficiency and scalability ST. PAUL, Minn., Oct. 29, 2021 /PRNewswire/ -- 3M Separation and Purification ...
2021-10-29 15:45
2307
Elekta establishes a framework for sustainability-linked bonds
STOCKHOLM, Oct. 29, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has established a Sustainability-Linked Bond Framework (SLB Framework) for issues of sustainability-linked bonds under itsMedium Term Note Program (MTN-Program). Elekta is among the first companies inSweden to est...
2021-10-29 15:29
3324
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC
SUZHOU, China, Oct. 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 inChina (ENREACH-LUNG-02) recently completed the first drug administration. ENREACH-LUNG-02 is a multi-center, open-label, randomized...
2021-10-29 09:36
3097
Hanmi Science Consortium Drives Ambitious Project for Worldwide Vaccine Equity
SEOUL, South Korea, Oct. 29, 2021 /PRNewswire/ -- Hanmi Science doesn't just want the world to know they are committed to vaccine equity, they want to prove it. Mr. Lim, CEO of Hanmi Science, echoes the concerns of Mr.Bill Gates, co-founder of the Bill & Melinda Gates Foundation. As Mr. Gates sta...
2021-10-29 09:27
3235
World Stroke Day: Global survey reveals only 35% hospitals worldwide provide essential stroke treatment
GENEVA, Oct. 29, 2021 /PRNewswire/ -- On World Stroke Day, 29 October, the World Stroke Organization (WSO) is calling for urgent action after a survey by the WSO and the World Health Organization (WHO) found that only 35% of hospitals worldwide provide essential clot-busting medicine tissue plasm...
2021-10-29 06:01
2024
ImmunoForge Inc. receives U.S. FDA ODD for PF1801
SEOUL, South Korea and SILVER SPRING, Md., Oct. 29, 2021 /PRNewswire/ -- ImmunoForge (Co-CEOsSung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 which is in development for treatment of D...
2021-10-29 05:50
4076
EZZ Marks Transition to Genomic Health Following Exceptional FY21 Performance
About EZZ Life Science Holdings EZZ Life Science Holding Limited (ASX:EZZ) is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papi...
2021-10-29 04:05
4546
FII Institute Announces Investment in AZmed, Helping to Address Global Shortage in Radiologists
RIYADH, Saudi Arabia, Oct. 28, 2021 /PRNewswire/ -- The Future Investment
Initiative (FII) Institute has announced a1 million EUR investment in AZmed,
developers of Artificial Intelligence-enabled diagnostic applications which can
help address the shortage of radiologists around the world.
2021-10-28 23:15
4204
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 327 media titles]
2026-08-05 11:34
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 301 media titles]
2026-08-06 15:10
MetaOptics Ltd achieves 79% of FY2025 full-year revenue in 1H 2026, on track to fulfil purchase orders of key metalens production equipment in 2H 2026
[Picked up by 292 media titles]
2026-08-11 19:03Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 291 media titles]
2026-08-10 19:12
Most Read
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
2026-08-05 11:34
20055
Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
2026-08-06 15:10
14666
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
8235